Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Effects of Eszopiclone Treatment (3mg for Two Months) to Counteract the Adverse Metabolic Consequences of Primary Insomnia

NCT00555750 is registered in ClinicalTrials.gov with Brigham and Women's Hospital as lead sponsor.

NCT NCT00555750
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00555750 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Effects of Eszopiclone Treatment (3mg for Two Months) to Counteract the Adverse Metabolic Consequences of Primary Insomnia
Lead sponsor
Brigham and Women's Hospital
Phase
Not applicable
Overall status
Completed
Start date
March 31, 2006
Completion date
August 31, 2008
Enrollment
20 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

primary insomnia